Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta A Miyares

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
JAMA Internal Medicine|July 7, 2015
One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation: Placing Real-World Results Into PerspectiveMarta A Miyares
The Annals of Pharmacotherapy|April 15, 2015
Comment: clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapyMarta A Miyares
Hospital Pharmacy|January 15, 2014
The attending pharmacist: roles and responsibilitiesMarta A Miyares
The Annals of Pharmacotherapy|January 6, 2011
Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitorsMarta A Miyares
JAMA Internal Medicine|March 5, 2014
Caution warranted when defining contraindications in initiating β-blocker therapyMarta A Miyares
The Annals of Pharmacotherapy|March 13, 2015
Comment: efficacy and safety of argatroban and bivalirudin in patients with suspected heparin-induced thrombocytopeniaMarta A Miyares
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 6, 2016
Predictions and presumptive treatment of heparin-induced thrombocytopeniaMarta A Miyares
The Annals of Pharmacotherapy|August 8, 2015
Comment: Pulmonary Embolism After Early Change From Rivaroxaban to Aspirin Following Total Knee Replacement in an Obese PatientMarta A Miyares
JAMA Internal Medicine|June 12, 2013
Additional considerations to precede selection of enoxaparin therapyMarta A Miyares
JAMA Internal Medicine|September 3, 2014
Progression to hepatitis and fibrosis secondary to lomitapide use: selecting the next course of actionMarta A Miyares
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
JAMA Internal Medicine|July 7, 2015
One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation: Placing Real-World Results Into PerspectiveMarta A Miyares
The Annals of Pharmacotherapy|April 15, 2015
Comment: clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapyMarta A Miyares
Hospital Pharmacy|January 15, 2014
The attending pharmacist: roles and responsibilitiesMarta A Miyares
The Annals of Pharmacotherapy|January 6, 2011
Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitorsMarta A Miyares
JAMA Internal Medicine|March 5, 2014
Caution warranted when defining contraindications in initiating β-blocker therapyMarta A Miyares
The Annals of Pharmacotherapy|March 13, 2015
Comment: efficacy and safety of argatroban and bivalirudin in patients with suspected heparin-induced thrombocytopeniaMarta A Miyares
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 6, 2016
Predictions and presumptive treatment of heparin-induced thrombocytopeniaMarta A Miyares
The Annals of Pharmacotherapy|August 8, 2015
Comment: Pulmonary Embolism After Early Change From Rivaroxaban to Aspirin Following Total Knee Replacement in an Obese PatientMarta A Miyares
JAMA Internal Medicine|June 12, 2013
Additional considerations to precede selection of enoxaparin therapyMarta A Miyares
JAMA Internal Medicine|September 3, 2014
Progression to hepatitis and fibrosis secondary to lomitapide use: selecting the next course of actionMarta A Miyares
Pageof 3